Daratumumab (IgG1κ), the first monoclonal CD38 antibody approved for multiple myeloma treatment [40, 41], has been explored off-label in AMR, with several case reports and series published to date [42–50]. This evidence concerns the gene CD38 and plasma cell myeloma.